Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Nom du journal : Lancet Oncol
Année : 2014
Volume : 15
Page de départ : 700
Page de fin : 712